SecBot SecBot
SECBOTREPLAY Home › Report › KRYS

KRYS · Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% YoY),…

Krystal Biotech, Inc. · 8-K filed Aug 3, 2026 at 07:04 ET

At the news

BULLISHIMPACT 6/10

8-K filed Aug 3, 2026 at 07:04 ET

Krystal Biotech reported Q2 2026 VYJUVEK revenue of $119.2M (+24% YoY), slightly below the $121.0M consensus, with GAAP diluted EPS of $1.79 vs. the Street consensus of $1.70, representing a beat. The company maintained its FY 2026 non-GAAP R&D and SG&A expense guidance of $175-195M. The quarter showed strong commercial execution with 730+ reimbursement approvals and 640+ prescribers, while the pipeline advanced with multiple registrational readouts expected in 2H 2026, including top-line data for KB803 in 4Q 2026. The slight revenue miss relative to consensus tempers the otherwise positive operational update, resulting in a neutral-to-modestly-bullish read.

  • Q2 2026 VYJUVEK global revenue of $119.2M, up 24% YoY from $96.0M
  • GAAP diluted EPS of $1.79, beating the $1.70 Street consensus
  • Revenue of $119.2M slightly below the $121.0M consensus estimate
  • Cash and investments of $1.1B, up from $955.9M at year-end 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access